Evaluating the Real-World Impact of Bevacizumab in Ovarian Cancer Treatment
A new study examines the real-world effectiveness of bevacizumab added to chemotherapy for ovarian cancer, highlighting benefits in high-risk patient groups and informing personalized treatment strategies.
A recent real-world study published in the journal Cancer has assessed the effectiveness of adding bevacizumab to first-line chemotherapy in patients with advanced ovarian cancer. The research used electronic health records from a cohort of 1,752 patients diagnosed between 2017 and 2023, with a median follow-up of 1.5 years. Findings indicate that, similar to previous clinical trials, the benefits of bevacizumab are primarily seen in specific high-risk patient groups.
Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), which inhibits tumor blood vessel formation and growth. While clinical trials have shown that adding bevacizumab to chemotherapy does not significantly extend overall survival across the entire patient population, subgroup analyses suggest that patients with high-risk prognostic factors—such as advanced disease stages or residual cancer post-surgery—may experience a longer median time to next treatment and a trend toward improved median overall survival.
Specifically, for high-risk patients, those receiving chemo plus bevacizumab had a median time to next treatment of 13.6 months compared to 11.7 months with chemotherapy alone. Additionally, there was a trend suggesting prolonged overall survival (31.1 vs. 27.4 months). Conversely, patients without high-risk factors did not show significant differences with the addition of bevacizumab.
Dr. Linda R. Duska from the University of Virginia emphasized that these real-world data align with clinical trial results, highlighting the importance for clinicians to evaluate individual patient risk profiles before incorporating bevacizumab into treatment plans. Overall, the study underscores that while bevacizumab may benefit certain subpopulations, its use should be tailored to those most likely to derive meaningful clinical advantages.
This research reinforces the notion that personalized treatment strategies remain crucial in ovarian cancer management and could guide future therapeutic decisions in clinical practice.
Source: https://medicalxpress.com/news/2025-05-bevacizumab-ovarian-cancer-trial-real.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Reversible Technique Targets Neural Circuits with Molecular Precision
A pioneering technique enables reversible, precise disruption of brain neural circuits using engineered proteins, opening new avenues for neuroscience research and potential therapies for neurological disorders.
Genomic Testing Using Chromosomal Instability Predicts Non-Responders to Cancer Chemotherapy
A new genomic test analyzing chromosomal instability patterns can predict which cancer patients will not respond to standard chemotherapy drugs, paving the way for personalized treatment strategies.
FDA Ends Sales of Off-Brand GLP-1 Medications Like Ozempic
The FDA has halted the sale of off-brand GLP-1 medications like Ozempic, raising safety and access concerns for patients relying on compounded drugs for weight loss and diabetes management.
Study Finds Pregnant Women in States with Abortion Restrictions Are More Likely to Lack Health Insurance and Access Necessary Care
Research shows that pregnant women in states with abortion restrictions are more likely to be uninsured and lack access to essential healthcare, risking poorer maternal outcomes. The study highlights disparities tied to Medicaid policies and restrictive laws.